RUBY News and Press, Rubius Therapeutics Inc. From 03/16/21

Rubius Therapeutics (RUBY) has upsized and priced a previously announced public offering of shares at $29/share.Proceeds from the offering of 6,896,552 shares are now expected to be $200M.The offering is expected to close on March 19.Rubius shares were up 1.4% to $32.45 in...

CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutic...

These Biotech Stocks Are Red Hot Right Now. Biotech stocks continue to show promise to investors who bet on them. Could this be the right time to jump on the biotech bandwagon? Opportunities for overnight astronomical gains could happen when biotech companies report successful c...

Can These Top Health Care Stocks Keep Up Their Momentum This Week? The health care sector continues to play a critical role in the economy. This could mean well for investors who have invested in health care stocks . Despite the pandemic placing an enormous strain on the global ...

Rubius Therapeutics (RUBY) announces that it has commenced an underwritten public offering of $150M of shares.Rubius also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares.Intends to use the net proceeds, together with its existing cash, cash ...

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeuti...

Shares of Rubius Therapeutics (RUBY) closed up 84.4% to $30.29 on Monday.Earlier today, Rubius released phase 1/2 data on RTX-240, its candidate for solid tumors, that the company says validates its clinical platform.Results for RTX-240 in, respectively, anal cancer and metastatic u...

Shares of clinical-stage biopharmaceutical company Rubius Therapeutics (NASDAQ: RUBY) are soaring through the roof on Monday following the company's release of data from an ongoing clinical trial for RTX-240, an experimental cancer treatment. Rubius Therapeutics' stock was up by 71....

Gainers: Sigma Labs (SGLB) +162%.Check-Cap (CHEK) +110%.Rubius Therapeutics (RUBY) +69%.Luokung Technology (LKCO) +43%.Shaw Communications (SJR) +38%.RumbleON (RMBL) +38%.Aeterna Zentaris (AEZS) +31%.Baosheng Media (BAOS) +30%.Intec Pharma (NTEC) +29%.GenMark Diagnostics (GNMK)...

Torchlight Energy Resources (TRCH) -15% on business combination timingRubius Therapeutics (RUBY) -14% on initial data for RTX-240 in solid tumorsEntera Bio (ENTX) -13%.Nova LifeStyle (NVFY) -12%.NLS Pharmaceutics (NLSP) -12%.Eli Lilly and Company (LLY) -7% after ...